
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc. has demonstrated robust growth, with its Telehealth active subscriber base increasing by 14% year-over-year, reaching 310,818 subscribers by the end of the third quarter of 2025. The company's total revenue for the period was reported at $60.2 million, reflecting a 12.7% year-over-year growth, with Telehealth revenue specifically rising 17.4% to $47.3 million, underscoring its strong market position. Additionally, the launch of new offerings, including Novo's GLP-1s at competitive pricing, alongside a solid investment in telehealth infrastructure, positions LifeMD for continued expansion and increased demand for its products and services.
Bears say
LifeMD Inc. reported a revenue of $60.2 million for the latest quarter, which represented a 13% year-over-year growth but fell short of consensus estimates, revealing concerns about slowing revenue growth, particularly in the Telehealth segment. The company's adjusted EBITDA of $5.1 million also missed expectations, exacerbating worries about its profitability trajectory amid reduced marketing of compounded products and increased competition in the healthcare space. Additionally, it revised its full-year revenue guidance downward, highlighting pressures from competitors and raising potential risks related to patient acquisition, profitability, and market positioning.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares